Tag: DS-8201
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...
In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...
Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...
Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...
Daiichi Sankyo Accelerates BLA Submission for [Fam-] Trastuzumab Deruxtecan in HER2...
Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...
Encouraging Preliminary Results in Treatment of Colorectal Cancer with Trastuzumab Deruxtecan
Updated Phase I safety and efficacy data for [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody-drug conjugate or ADC, were presented at the 2018 annual congress of the European Society for Medical Oncology - ESMO 2018, in Munich, Germany for a subgroup of patients with heavily pretreated HER2 expressing colorectal cancer.
Updated Results for [Fam-] Trastuzumab Deruxtecan in Patients with HER2 Mutated...
Updated phase I safety and efficacy data for trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC) being developed by Daiichi...
DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...
DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...
Global Phase II Study of DS-8201 in Patients with HER2-Expressing Advanced...
Following initiation of pivotal phase II studies in HER2-positive breast cancer and gastric cancer, the initiation of a third phase II study in colorectal...
Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response...
Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...
First Patient Dosed in Pivotal Phase II DESTINY-Gastric01 Study of DS-8201
A first patient has been enrolled in DESTINY-Gastric01 (NCT03329690), a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy...
New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors Warrants Further...
In clinical trials, trastuzumab deruxtecan or DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated preliminary antitumor activity in...
